公开(公告)号：US20170327544A1

公开(公告)日：2017-11-16

申请号：US15663867

申请日：2017-07-31

申请人： International AIDS Vaccine Initiative

发明人： Christopher L. PARKS ,  Ivo Lorenz ,  Sanjay K. Phogat ,  Timothy J. Zamb

IPC分类号： C07K14/005 ,  A61K39/21 ,  C12N7/00 ,  A61K39/12 ,  G01N33/68 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5256 ,  C12N7/00 ,  C12N2740/16051 ,  C12N2740/16134 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20251 ,  G01N33/6854 ,  G01N2333/162

摘要： The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

公开(公告)号：US20170233441A1

公开(公告)日：2017-08-17

申请号：US15508885

申请日：2015-09-04

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Serv

发明人： Peter Kwong ,  Marie Pancera ,  Tongqing Zhou ,  Ivelin Georgiev ,  Michael Gordon Joyce ,  Priyamvada Acharya ,  Jason Gorman ,  Yongping Yang ,  Aliaksandr Druz ,  Guillaume Stewart-Jones ,  Rita Chen ,  Gwo-Yu Chuang ,  Ulrich Baxa ,  John Mascola ,  Rebecca Lynch ,  Baoshan Zhang ,  Cheng Cheng

IPC分类号： C07K14/435 ,  A61K39/21 ,  G01N33/569 ,  C07K16/10

CPC分类号： C07K14/435 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55577 ,  C07K14/005 ,  C07K16/1063 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2469/20

摘要： HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

公开(公告)号：US20170159139A1

公开(公告)日：2017-06-08

申请号：US15436065

申请日：2017-02-17

申请人： Laboratory Corporation of America Holdings

发明人： Wei Huang ,  Signe Fransen ,  Christos Petropoulos ,  Jonathan Toma ,  Jeannette Whitcomb

IPC分类号： C12Q1/70

CPC分类号： C12Q1/703 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  G01N2800/52

摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.

公开(公告)号：US09611294B2

公开(公告)日：2017-04-04

申请号：US13612300

申请日：2012-09-12

申请人： Timothy Cardozo ,  Xiangpeng Kong ,  Susan Zolla-Pazner

发明人： Timothy Cardozo ,  Xiangpeng Kong ,  Susan Zolla-Pazner

IPC分类号： C07K7/64 ,  A61K38/19 ,  A61K39/21 ,  A61K39/12 ,  C07K7/08 ,  C07K14/005 ,  C07K14/245 ,  C07K16/10 ,  C07K14/28 ,  G01N33/68 ,  G01N33/569 ,  A61K39/00

CPC分类号： C07K16/1063 ,  A61K38/19 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/545 ,  A61K2039/6037 ,  A61K2039/64 ,  C07K7/08 ,  C07K7/64 ,  C07K14/005 ,  C07K14/245 ,  C07K14/28 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/55 ,  C12N7/00 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2799/023 ,  G01N33/56988 ,  G01N33/6854 ,  G01N2333/162 ,  G01N2469/20

摘要： The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.

公开(公告)号：US20160313325A1

公开(公告)日：2016-10-27

申请号：US15208358

申请日：2016-07-12

申请人： KFLP BIOTECH, LLC

发明人： Andrey Vinnik ,  Peter Fedichev ,  Maxim Kholin ,  Christopher Molloy ,  Aron Katz

IPC分类号： G01N33/566 ,  G06F19/00 ,  G06F19/16 ,  C40B30/02 ,  C07C237/42 ,  C07C231/12

CPC分类号： G01N33/566 ,  A61K31/00 ,  C07C231/12 ,  C07C237/40 ,  C07C237/42 ,  C07C2601/14 ,  C07K14/005 ,  C07K16/1063 ,  C07K2317/14 ,  C12N7/00 ,  C12Q1/703 ,  C40B30/02 ,  G01N33/50 ,  G01N2333/162 ,  G01N2333/70514 ,  G01N2500/00 ,  G01N2500/02 ,  G06F19/16 ,  G06F19/706

摘要： The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.

摘要翻译： 本发明涉及一种设计HIV（人类免疫缺陷病毒）糖蛋白（gp）120与CD4受体或整联蛋白α4β7（a4b7）结合的抑制剂的方法。 抑制剂与gp120的三维结构内的六个基序中包含的至少两个氨基酸残基相互作用。 还提供了化合物，其药物组合物及其在开发HIV gp120与CD4受体或整联蛋白α4β7（a4b7）结合的抑制剂中的用途。 抑制剂可用于预防或治疗HIV感染和/或与HIV感染相关的疾病。

公开(公告)号：US20160304874A1

公开(公告)日：2016-10-20

申请号：US15101292

申请日：2014-12-02

申请人： BRANDEIS UNIVERSITY

发明人： Isaac J. KRAUSS

IPC分类号： C12N15/117 ,  A61K39/21 ,  C12P19/34 ,  G01N33/53 ,  G01N33/68 ,  C12N15/10

CPC分类号： C12N15/117 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/572 ,  A61K2039/585 ,  C12N15/1058 ,  C12N2310/16 ,  C12N2310/17 ,  C12N2310/351 ,  C12N2310/531 ,  C12N2320/30 ,  C12P19/34 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5308 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/6854 ,  G01N2333/162 ,  G01N2333/9121 ,  Y02A50/57

摘要： The invention relates to an oligonucleotide including one or more modified nucleoside bases having the structure -B-L-A wherein for each of the modified nucleosides A is independently a monosaccharide or oligosaccharide, L is a linker molecule, and B is independently a pyrimidine or pyridine base linked to the sugar-phosphate backbone of the oligonucleotide; and wherein the oligonucleotide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the oligonucleotide, and pharmaceutical compositions that include the oligonucleotide or the immunogenic conjugate are also disclosed. Various method of using the oligonucleotides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody. A method is also disclosed for selecting the oligonucleotides using an alternative Selection of Modified Aptamers (SELMA).

摘要翻译： 本发明涉及包含一个或多个具有结构-BLA的修饰的核苷碱基的寡核苷酸，其中对于每个修饰的核苷A，A独立地是单糖或寡糖，L是连接分子，B独立地是与 寡核苷酸的糖 - 磷酸骨架; 并且其中寡核苷酸以小于100nM的亲和力特异性结合与碳水化合物结合的单克隆抗体。 还公开了包含寡核苷酸的免疫原性缀合物和包含寡核苷酸或免疫原性缀合物的药物组合物。 公开了使用寡核苷酸，免疫原性缀合物和药物组合物的各种方法，包括诱导免疫应答，抑制病毒或细菌感染，治疗癌症和检测中和抗体。 还公开了使用修饰的选择性选择（SELMA）来选择寡核苷酸的方法。

公开(公告)号：US20160152666A1

公开(公告)日：2016-06-02

申请号：US14972272

申请日：2015-12-17

申请人： International AIDS Vaccine Initiative

发明人： Christopher L. PARKS ,  Ivo Lorenz ,  Sanjay K. Phogat ,  Timothy J. Zamb

IPC分类号： C07K14/005 ,  G01N33/68 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5256 ,  C12N7/00 ,  C12N2740/16051 ,  C12N2740/16134 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20251 ,  G01N33/6854 ,  G01N2333/162

摘要： The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

公开(公告)号：US20140134606A1

公开(公告)日：2014-05-15

申请号：US14159612

申请日：2014-01-21

申请人： MOREHOUSE SCHOOL OF MEDICINE

发明人： Gale W. NEWMAN ,  Sam Anyanwu

IPC分类号： C12Q1/70

CPC分类号： G01N33/56988 ,  C12Q1/70 ,  C12Q1/703 ,  C12Q1/706 ,  C12Q1/707 ,  G01N1/40 ,  G01N33/493 ,  G01N33/56983 ,  G01N33/576 ,  G01N33/6893 ,  G01N2333/02 ,  G01N2333/10 ,  G01N2333/161 ,  G01N2333/162 ,  G01N2333/163 ,  G01N2333/186 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/56

摘要： A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.

摘要翻译： 公开了一种用于诊断受试者中基于肝炎病毒相关生物标志物的肝炎病毒感染或肝炎病症的方法，所述肝炎病毒相关生物标志物存在于来自受试者的体液样品中的外来体上。 还公开了一种用于监测受试者中肝炎病毒感染或肝炎疾病状况的过程的方法以及基于存在于外来体上的肝炎病毒相关生物标志物来监测具有抗肝炎病毒剂的受试者治疗有效性的方法 来自受试者的体液样本，以及用于诊断受试者中基于肝炎病毒相关生物标志物的肝炎病毒感染和/或肝炎疾病状况的试剂盒，其来自受试者的体液样品中的外来体。

公开(公告)号：US20130143202A1

公开(公告)日：2013-06-06

申请号：US12977411

申请日：2010-12-23

申请人： Hana Golding ,  Surender Khurana

发明人： Hana Golding ,  Surender Khurana

IPC分类号： G01N33/68 ,  C07K14/16

CPC分类号： G01N33/6854 ,  C07K14/005 ,  C07K14/161 ,  C07K14/162 ,  C07K14/163 ,  C12N2740/16111 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16322 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2469/20

摘要： This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.

公开(公告)号：US20130071424A1

公开(公告)日：2013-03-21

申请号：US13612300

申请日：2012-09-12

申请人： Timothy CARDOZO ,  Xiangpeng KONG ,  Susan ZOLLA-PAZNER

发明人： Timothy CARDOZO ,  Xiangpeng KONG ,  Susan ZOLLA-PAZNER

IPC分类号： C07K7/08 ,  C07K7/64 ,  A61K38/19 ,  C07K16/10 ,  G01N33/68 ,  C07K14/245 ,  C07K14/28 ,  A61K39/21

CPC分类号： C07K16/1063 ,  A61K38/19 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/545 ,  A61K2039/6037 ,  A61K2039/64 ,  C07K7/08 ,  C07K7/64 ,  C07K14/005 ,  C07K14/245 ,  C07K14/28 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/55 ,  C12N7/00 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2799/023 ,  G01N33/56988 ,  G01N33/6854 ,  G01N2333/162 ,  G01N2469/20

摘要： The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.

摘要翻译： 本发明涉及包含HIV表面包膜糖蛋白gp120的V2环片段的分离的免疫原性肽。 该肽与已经显示出对HIV-1感染保护的疫苗接种的患者的血液中的抗体特异性结合，不与没有接受疫苗的匹配患者的血液反应，因此可以引起抗HIV-1 抗HIV-1感染的抗体。 本发明的其它方面涉及包含插入免疫原性支架蛋白的肽的分离的免疫原性多肽，由免疫原性肽和免疫学或药学上可接受的载体或赋形剂组成的疫苗组合物以及诱导针对HIV的免疫应答的方法 -1和检测HIV-1的方法。